FindTrial
Sign In

Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction:a clinical observation study

Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002267
Enrollment
Unknown
Registered
2012-04-22
Start date
2009-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

SDS intervention group:Salidroside intervention+Epirubicin chemotherapy
Epirubicin group:Epirubicin chemotherapy

Sponsors

Affiliated Jiangyin Hospital of Southeast University Medical College
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients aged between 18 and 68 years, an echocardiographic left ventricular ejection fraction(LVEF) value>=50%. All patiets with histologically confirmed breast cancer, previously untreated. Patients were all candidates to be treated with an epirubicin -based chemotherapy regimen (maximal cumulative dose of 400+/-40 mg/m2) according to the international standardized protocols for breast cancer.

Exclusion criteria

Exclusion criteria: Patients were not eligible if they had a history of coronary heard disease, hypertension, or diabetes mellitus and/or had been previously treated with chest irradiation.

Design outcomes

Primary

MeasureTime frame
myocardial strain rate;left ventricular ejection fraction;—

Countries

China

Contacts

Public ContactShen Wei-sheng
gaochh@yahoo.com+86 13093113280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026